Twist Bioscience officer proposes $4.86M share sale
Twist Bioscience's reported share count is 62,707,424 outstanding shares, apart from Patrick Finn's proposed sale.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Patrick Finn, an officer of Twist Bioscience Corp, gave notice of a proposed sale of 25,714 common shares at an aggregate market value of $4,856,958.03, with an approximate sale date of October 2, 2026. The shares came from restricted stock vesting on October 1, 2026; the sale includes an amount necessary for a tax obligation from settlement of a vested equity award distribution. Earlier reported sales were 2,238 shares on July 23, 2026; 2,888 on August 3, 2026; 78,355 on August 18, 2026; and 4,046 on August 21, 2026.
Key Figures
Key Terms
Rule 144 regulatory
Restricted Stock Vesting financial
aggregate market value financial
vested equity award distribution financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.